- Home
- ATYR
as of 12-10-2025 3:46pm EST
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
| Founded: | 2005 | Country: | United States |
| Employees: | 59 | City: | SAN DIEGO |
| Market Cap: | 79.2M | IPO Year: | 2015 |
| Target Price: | $8.75 | AVG Volume (30 days): | 3.0M |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.84 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.64 - $7.29 | Next Earning Date: | 11-06-2025 |
| Revenue: | $190,000 | Revenue Growth: | -19.15% |
| Revenue Growth (this year): | -52.26% | Revenue Growth (next year): | 18728.88% |
AI-Powered ATYR Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Compare ATYR vs Leading Stocks
See how ATYR stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ATYR aTyr Pharma Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.